Overview
Per Xinhua Finance, 23 insurers have raised over 80 billion yuan this year via special treasury injection, shareholder capital increases and strategic investors; another 19 insurers completed or won approval for 21 bond issuances totaling about 60 billion yuan, of which 69.9 billion (nearly 70%) were perpetual bonds, surpassing traditional capital-supplement bonds in scale for the first time. At end-Q2 2026, the average comprehensive solvency ratio was 180.6% and core ratio 133.5% — well above regulatory red lines — yet some small and mid-sized insurers sit near the boundary.
Background & Interpretation
1. Regulatory and Industry Context
From 2026, the Solvency II Phase II transition ended and stricter capital and risk-measurement rules fully took effect, lifting minimum capital by about 5%–8% on average; for property insurers, higher non-auto risk weights raised minimum capital ~7.5%. Simultaneously, unlisted insurers adopted new financial-instrument and insurance-contract standards in 2026, where spot-rate discounting lifts reserves and directly hits net assets. The twin pressures released concentrated recapitalization demand.
2. Core Drivers and Mechanisms
“Blood replenishment” runs on two tracks: equity via treasury injection into state insurers, shareholder top-ups and strategic investors; debt via perpetual and capital-supplement bonds. Perpetuals’ surge reflects preference for non-dilutive, core-capital-eligible instruments — but capital is not free; high-coupon perpetuals erode profit and must match business pace.
3. Market Structure and Industry Impact
Capital concentrates toward leaders and compliance-strong players; small insurers unable to recapitalize may face business limits or even regulatory measures. At end-Q2, five insurers (Huahui, Anhua, Changsheng, Qianhai, Asia-Pacific) were non-compliant, with several others near key scrutiny lines — industry divergence is widening.
Implications & Outlook
Near term, the equity and bond windows stay active, with treasury injection and diverse tools in parallel. Mid term, as Phase II rigidifies and new standards deepen, competition shifts from scale to capital efficiency and risk control; dividend-insurance transformation and non-auto governance also need capital backing.
Takeaways for Industry Participants
Insurers should plan capital ahead, balancing equity and debt against business mix and solvency targets. Investors must distinguish true operating quality behind “recapitalization” and beware of masking weak earnings with capital. Regulators and markets should jointly enrich the capital toolkit for stable development.
This column compiles industry information and shares technical perspectives; it does not constitute investment advice.